Abstract
In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice. The focus now turns to novel therapeutic targets to optimize renoprotection as diabetic kidney disease grows to epidemic proportions worldwide.
| Original language | English |
|---|---|
| Pages (from-to) | 68-70 |
| Number of pages | 3 |
| Journal | Nature Reviews Nephrology |
| Volume | 15 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1 Feb 2019 |